Rivaroxaban in Patients with Recent Acute Coronary Syndrome - The New England Journal of Medicine - 2012
Brief Summary:
In patients with recent ACS, the addition of rivaroxaban to standard dual antiplatelet therapy reduced the composite of CV mortality, recurrent MI, or stroke, but increased the risk of nonfatal bleeding.Reference:
http://www.ncbi.nlm.nih.gov/pubmed/22077192
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you